ABSTRACT
Background Improvements in malaria control have stalled recently and new tools are needed. The R21 vaccine is comprised of the malaria circumsporozoite protein fused to hepatitis B surface antigen (HBsAg). It forms particles that lack the excess HBsAg in the frequently tested malaria vaccine candidate, RTS,S/AS01B.
Methods We conducted an open-label, first-in-human, Phase Ia study evaluating safety and immunogenicity of R21 administered alone and with the saponin-based adjuvant, Matrix-M™ (MM). Twenty-eight healthy adults received three doses of R21 given intramuscularly 4 weeks apart. We subsequently conducted a Phase Ib randomised, controlled trial in West African adults.
Findings Vaccinations were well tolerated, and the majority of local and systemic adverse events were mild. Reactogenicity was significantly lower in Burkinabe than UK vaccinees (p<0.0001). Antibody responses increased significantly 28 days after the 2nd vaccination in UK volunteers. Antibody responses to R21 in all dose groups (2μg, 10μg and 50μg) were comparable to those of 50μg RTS,S/AS01B in malaria-naïve adults at 28 days after final vaccination. The 10μg dose induced more durable responses, with 2-fold higher NANP-specific IgG titres at 6 months compared with the 2μg and 50μg dose groups. R21 also boosted baseline humoral responses in Burkinabe adults with well-maintained responses suggesting natural boosting.
Interpretation R21 adjuvanted with MM is safe and has comparable immunogenicity to RTS,S/AS01B, even when administered at a five-fold lower 10μg dose in UK and African populations. This forms the basis for efficacy testing of this vaccine which could prove to be particularly cost-effective to manufacture and deploy.
Competing Interest Statement
KAC, NaV, SCG, KJE and AVSH are named as co-inventors or contributors on patent filings related to the R21 vaccine candidate. All are or were University of Oxford students and / or employees.
Clinical Trial
NCT02572388,NCT02925403
Clinical Protocols
https://ora.ox.ac.uk/objects/uuid:b8f96d59-8042-4271-a600-29545676f0
https://ora.ox.ac.uk/objects/uuid:e4d463f1-9d95-4f6b-a47d-fcb36281f97d
Funding Statement
Vaccine manufacture was funded by the UK Medical Research Council (Grant no: MR/JOO8680/1) and the European Commission FP7 programme (Grant no: 305282). The study in Burkina Faso was supported by a Strategic Primer grant award from the European and Developing Countries Clinical Trials Partnership (EDCTP) with co-funding from Swedish International Development Cooperation Agency (Sida); UK Medical Research Council; Irish Aid, Department of Foreign Affairs and Trade, Ireland; and Bundesministerium für Bildung und Forschung (BMBF), Germany. It was performed as part of the work programme of the EDCTP Malaria Vectored Vaccines Consortium 2 (MVVC2), (grant number SP.2011.41304.025). The European Vaccine Initiative (EVI) coordinated the EDCTP-funded MVVC project. Odile Leroy was executive director of EVI at the time of the study. N.K.V. is an employee of EVI. The work was also supported by the UK National Institute of Health Research through the Oxford Biomedical Research Centre (http://oxfordbrc.nihr.ac.uk/) (A91301 Adult Vaccine) and the Wellcome Trust (https://www.wellcome.ac.uk/) (084113/Z/07/Z).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Footnotes
↵^ Deceased
Data Availability
All data related to this study is contained in the manuscript.
